Pfizer Inc. (NYSE:PFE) is one of the best inexpensive stocks to buy now. On January 20, Novavax announced a non-exclusive licensing agreement with Pfizer, granting the pharmaceutical giant access to ...

Pfizer has spent billions of dollars on acquisitions in the past few decades. Its biggest deals include Warner-Lambert, ...

Pfizer is exiting its HIV-focused joint venture, ViiV Healthcare, while reshaping its portfolio around other therapeutic ...

Earlier in January 2026, Novavax announced a non-exclusive license and option agreement granting Pfizer worldwide rights to ...

Novavax (NVAX) shares added ~5% in the premarket on Tuesday after the COVID-19 vaccine maker reached a licensing deal with ...

Pfizer’s revenue soared to record heights a few years ago thanks to its coronavirus products, but growth has since slowed. The company is counting on new products, and a focus on oncology, to drive ...

Pfizer’s multi-year effort to stabilize its U.S. penicillin supply has hit an unexpected hitch after particulate concerns prompted a recall of the company’s long-acting injectable form of the ...

Pfizer is a Buy at low valuation but faces a 2030 patent cliff, COVID sales declines, and LOE risks. Click here to read an analysis of PFE stock now.

Pfizer's post-pandemic revenue decline is temporary; new launches like Abrysvo and Adcetris, plus Seagen integration, position it for a 2025 turnaround. Valuation is compelling: Pfizer trades at deep ...

In this May 4, 2014 photo, the Pfizer logo is displayed on the exterior of a former Pfizer factory in the Brooklyn borough of New York. (AP Photo/Mark Lennihan, File) Updated at 10:58 a.m. NEW YORK • ...

Pfizer's second-quarter results were better than expected. The drugmaker will still face some near-term uncertainty. However, its long-term prospects look attractive, especially at current levels.